ストックスクリーナーアプリを入手
28.95
3.33%
-1.015
前日終値:
$29.97
開ける：
$29.74
24時間の取引高:
8.12M
Relative Volume:
0.45
時価総額：
$6.76B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
55.46
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
-2.32%
1か月 パフォーマンス:
-15.73%
6か月 パフォーマンス:
+77.74%
1年 パフォーマンス:
-40.05%
1日の値動き範囲:
$28.54
$30.10
1週間の範囲:
$28.54
$32.29
52週間の値動き範囲:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
28.96 | 6.99B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.39 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.16 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.80 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.40 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
501.57 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 開始されました | JP Morgan | Overweight |
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Utah sues Hims over alleged 'subscription trap,' sharing of private health data - St. George News
Securities Fraud Investigation Into Hims & Hers Health, - GlobeNewswire
FTC lawsuit alleges Hims & Hers charged consumers for unwanted prescriptions - Top Class Actions
HIMS SHAREHOLDER ALERT: Hims & Hers Health, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
A Major Telehealth Company Will Sell Longevity Peptides That Clinical Evidence Has Not Yet Backed - Medical Daily
Hims & Hers upgrades women's health app with AI, smart scale integration - TechTarget
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Hims & Hers Health, Inc. (HIMS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Hims & Hers shared patient health data with Meta, Snap and other advertisers, new class action lawsuit claims - Claim Depot
NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm - Morningstar
As Hims prepares for peptides launch, Wall Street cautious on prospects this year - Reuters
Investigation launched into Hims & Hers for all... - Pluang
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS) - marketscreener.com
Hims & Hers’ Revenue Beat Came With a Profitability Problem - MarketBeat
Hims & Hers: The Guidance Raise Doesn't Fix The Margin Problem (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health (HIMS) Stock Looks Cheap Even With Legal Risk - Yahoo Finance
Hims & Hers Health: Algorithmic Transformation of Consumer Healthcare - healthcare.digital
Hims & Hers Q2 Revenue Jumps 38% as International Expansion Accelerates - globalcosmeticsnews.com
HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide - TradingView
Hims & Hers Health, Inc. Signals Aggressive Growth Path - TipRanks
Hims & Hers Health, Inc. (HIMS) Stock forecasts - Yahoo Finance Singapore
A Look at Hims & Hers Health Inc (HIMS) After 4.0% Decline -- GF Value $40.71 vs Price $30.51 - GuruFocus
Hims & Hers planning to sell compounded peptides - The Hill
Hims & Hers Health (NYSE:HIMS) Price Target Cut to $33.00 by Analysts at Citigroup - MarketBeat
FTC Continues Investigation into Hims & Hers Health, Inc. - GlobeNewswire
HIMS Maintained by Morgan Stanley -- Price Target Raised to $28 - GuruFocus
HIMS Maintained by B of A Securities -- Price Target Raised to $32.00 - GuruFocus
HIMS Maintained by Deutsche Bank -- Price Target Raised to $26 - GuruFocus
HIMS Maintains Hold by TD Cowen -- Price Target Raised to $30 - GuruFocus
Bank of America Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock - MarketBeat
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $32.23, Implies 1% Upside - TradingView
Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down - Yahoo Finance
Will Hims & Hers’ Higher 2026 Revenue Guidance Amid Rising Losses Change HIMS’s Investment Narrative? - Yahoo Finance
Hims & Hers Health (NYSE:HIMS) Shares Gap DownTime to Sell? - MarketBeat
Hims & Hers stock trims losses following quarterly results - Yahoo Finance
Hims & Hers Health (HIMS) Faces Profitability Concerns Amid Stro - GuruFocus
Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst - benzinga.com
Citi Says Hims & Hers’ Full-Year Outlook Indicates ‘Hefty’ Q4 Earnings Lift, Warns Of Execution Risks - TradingView
Hims & Hers Health Sees Mixed Q2 as Gross Margin, FCF Weigh, Morgan Stanley Says - Yahoo Finance
Hims & Hers shares slide as costly weight-loss push squeezes margins - Reuters
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $31.85 - TradingView
Hims & Hers Health Slides on Wider-Than-Expected Q2 Loss - Schaeffer's Investment Research
HIMS Q2 Earnings Call Focuses on AI and Global Expansion - TradingView
HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook - TradingView
Why Is Hims & Hers Health Stock Falling Tuesday? - benzinga.com
Hims & Hers' Revenue Growth Comes at a Cost - Yahoo Finance
Canaccord reiterates Hims & Hers stock rating after Q2 beat - Investing.com
Hims & Hers Raises Outlook as Cash Flow Weakens - TradingView
Hims & Hers Health, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Needham raises Hims and Hers stock price target on GLP-1 growth - Investing.com
Needham & Company LLC Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price - MarketBeat
Hims & Hers Q2 2026 earnings: loss despite revenue beat - qz.com
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
1.13%
0.16%
大文字化:
|
ボリューム (24 時間):